Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Rating of “Hold” by Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have earned a consensus recommendation of “Hold” from the fourteen brokerages that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $487.3636.

MEDP has been the topic of a number of research analyst reports. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a report on Friday. Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Leerink Partners lowered their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a report on Wednesday.

Insider Buying and Selling

In other news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August J. Troendle sold 59,025 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the sale, the chief executive officer owned 774,602 shares in the company, valued at $470,787,603.56. The trade was a 7.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 264,486 shares of company stock valued at $159,549,049. 20.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Medpace

Institutional investors have recently modified their holdings of the company. Quent Capital LLC acquired a new position in Medpace during the 3rd quarter valued at about $25,000. Optiver Holding B.V. acquired a new stake in shares of Medpace in the third quarter valued at approximately $27,000. Geneos Wealth Management Inc. raised its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Medpace during the fourth quarter worth approximately $30,000. Finally, Elyxium Wealth LLC acquired a new position in shares of Medpace during the fourth quarter worth approximately $30,000. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 2.9%

Shares of NASDAQ:MEDP opened at $428.03 on Monday. The firm has a market cap of $12.15 billion, a PE ratio of 27.98, a price-to-earnings-growth ratio of 2.05 and a beta of 1.42. The company has a fifty day simple moving average of $567.52 and a 200 day simple moving average of $539.06. Medpace has a 12-month low of $250.05 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm’s revenue for the quarter was up 32.0% compared to the same quarter last year. During the same period last year, the business earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts forecast that Medpace will post 12.29 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.